Drug-Eluting stents (DES) now enter a new dimension...

The "proof of principle" of Paclitaxel-Eluting stents has already been confirmed.

Now

- the combination of the PICO cobalt-chromium stent and

- a biostable polymer coating containing Paclitaxel offers lower restenosis in de novo lesions.


The advantage of cobalt-chromium...
- very low profile
- high flexibility
- high radial strength
- ultra thin strut thickness
- superior to stainless steel


The PICO^Elite polymer coating is an ultra-thin biocompatible elastomer containing Paclitaxel - a drug-in-polymer matrix - with excellent properties:

- highly elastic with excellent strength and hardness
- resistant to high temperatures
- controlled-release kinetics
- homogeneous and uniform coverage

The asymmetrical ultra-thin coating (ratio 3:1) ensures higher radial diffusion gradient of Paclitaxel from stent to arterial intima. In the first 48 hours, approx. 30% of the total available dose of Paclitaxel is released. The PICO^Elite release rate chosen ensures continuous release of drug over the first 4 weeks. In this critical post-deployment phase, most of the drug is released in a controlled manner. Growth within the artery is inhibited; overall results at follow-up show lower binary restenosis.